Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.jbc.2021.100601

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publisher：Journal of Biological Chemistry  

Glioblastoma (GBM) is the most common and aggressive form of malignant brain cancer, with a poor prognosis and a 5-year survival rate of approximately 15%. The malignancy of GBM, including its treatment resistance and high recurrence rate, is largely attributed to the presence of cancer stem cells. Recent studies have identified the N-acetyltransferase 10 (NAT10), an enzyme responsible for catalyzing N<inf>4</inf>-acetylcytidine (ac4C) modification in RNA, as a key factor in cancer biology, with diverse roles across multiple cancer types. However, the specific contribution of this RNA modification to the malignancy of GBM remains unexplored. Here, we demonstrate that NAT10 expression is associated with poor prognosis in GBM patients and that NAT10 promotes GBM malignancy by enhancing stemness properties in human GBM cell line U251 and A172. A search for the underlying mechanism of NAT10-mediated enhancement of GBM stemness led to identification of polycomb repressive complex 2 (PRC2)-related genes as an epigenetic regulator. NAT10 mediates the acetylation of the coding region of Jumonji and AT-rich Interaction Domain containing 2 (JARID2) mRNA, which results in increased mRNA stability and elevated protein levels. Notably, the knockdown of JARID2 significantly reduced GBM stemness, suppressed tumor growth, and extended the survival of xenograft mice. Our findings suggest that NAT10-mediated acetylation of JARID2 mRNA up-regulates its protein levels, thereby promoting stemness and contributing to the malignancy of GBM. Targeting this NAT10-JARID2 axis may represent a novel therapeutic approach for treatment of GBM.

DOI： 10.1016/j.jbc.2025.108544

Scopus

PubMed

Language：English   Publisher：Supportive Care in Cancer  

Purpose: Paclitaxel and albumin-bound paclitaxel are important anticancer drugs for the treatment of non-small cell lung, pancreatic, gastric, and gynecological cancers; however, they cause peripheral neuropathy as an adverse reaction. Therefore, prophylaxis and treatment for peripheral neuropathy are needed, since there are no sufficient evidence-based strategies to prevent it. Our previous animal research and adverse effect database analysis studies have identified the potential of α1 antagonists to attenuate paclitaxel-induced peripheral neuropathy (PIPN). The purpose of the present study was to investigate the prophylactic potential of α1 antagonists for PIPN in patients with cancer. Methods: Data were collected from the medical records of 673 male patients aged 18 years and older who started treatment with paclitaxel- or albumin-bound paclitaxel-containing regimens at Kyushu University Hospital between January 1, 2013, and December 31, 2019. The two primary outcome measures were PIPN occurrence and paclitaxel discontinuation due to PIPN. Kaplan–Meier curves were generated for cumulative doses and evaluated using the log-rank test. Results: The percentage of patients in whom PIPN occurred (any grade) during the entire study period was 37.4% and 20.0% in without and with α1-receptor antagonist groups, respectively (P = 0.0101, χ² test). The incidence of PIPN (any grade) was significantly lower in the α1 antagonists combination group (N = 55) than in the no α1-receptor antagonists group (N = 618) (P = 0.0425, log-rank test). However, there were no significant differences between the two groups in the discontinuation of paclitaxel due to PIPN (P = 0.9654). Conclusions: The present retrospective cohort study may suggest that concomitant use of α1-receptor antagonists may moderate the development of PIPN.

DOI： 10.1007/s00520-025-09368-y

Scopus

PubMed

Language：English   Publisher：Biochemical and Biophysical Research Communications  

Circadian rhythm alterations are related to the onset and severity of various diseases. The expression of the dopamine receptor D3 (DRD3) is regulated by clock genes, and DRD3 functional abnormalities are linked to various neurological diseases. However, the relationship between DRD3 function and circadian machinery is unclear. Here, we demonstrate the influence of DRD3 on the circadian machinery. Although the expression of DRD3 in mouse suprachiasmatic nucleus (SCN) did not show a circadian rhythm, the expression of Per1 mRNA was altered in the SCN of Drd3 knockout (Drd3^−/−) mice compared to that in wild-type (WT) mice. These differences were caused by the upregulation of the DRD3–extracellular signal–regulated kinase–cAMP response element binding protein (DRD3–ERK–CREB) signaling pathway in cultured cells and SCN. In addition, Drd3^−/− mice demonstrated increased period length of locomotor activity than WT mice only under constant dark conditions. Expression of clock genes in the liver, which does not express DRD3, was affected by the loss of DRD3 only under constant dark conditions, similar to that in the SCN. These results suggest that DRD3 expressed in the SCN regulates the central clock via endogenous ligands and affects peripheral organs. This may provide new evidence to unravel the relationship between dopamine neurotransmission and the circadian clock, which has not yet been fully elucidated.

DOI： 10.1016/j.bbrc.2025.151470

Scopus

PubMed

Language：English   Publisher：Theranostics  

Rationale: Macrophage phagocytosis plays a role in cancer immunotherapy. The phagocytic activity of macrophages, regulated by circadian clock genes, shows time-dependent variation. Intervening in the circadian clock machinery of macrophages is a potentially novel approach to cancer immunotherapy; however, data on this approach are scarce. Microcurrent stimulation (MCS) promotes inflammation, proliferation, and remodeling, suggesting its potential to modulate macrophage function; however, its application has been limited. In this study, we investigated the impact of MCS on macrophage phagocytosis of cancer cells using mouse/human macrophage cell lines and various mouse/human cancer cell lines. Methods: Cells and mice received 300 µA, 400 Hz bidirectional pulsed MCS. Gene expression, protein expression, and phagocytosis activity were assessed in intraperitoneal macrophages collected from mice, as well as in RAW264.7, and THP-1 cells. Flow cytometry, population, phagocytosis activity, RNA-seq, and immunohistochemistry analyses were performed. Results: Noninvasive MCS prevented time-dependent reduction in macrophage phagocytosis of cancer cells by modulating the circadian clock genes. MCS also enhanced phagocytosis in mouse RAW264.7 and human THP-1 cells across various cancer types by promoting actin polymerization; similar in vivo effects were observed in mice. This enhancement occurred in abdominal macrophages of both sexes and was mediated by changes in clock gene expression. Specifically, suppressing the clock gene Per1 nullified the effects of MCS. Moreover, although macrophage phagocytosis typically declined during the dark period, MCS during the light period prevented this reduction. MCS also increased phagocytosis of peritoneally implanted cancer cells (4T1, ID8, and Hepa1-6) in mice, significantly reducing tumor engraftment and growth, and ultimately improving prognosis. Conclusions: The findings of this study suggest that targeting macrophage circadian mechanisms via MCS could enhance cancer immunity, offering new avenues for cancer immunotherapy.

DOI： 10.7150/thno.100748

Scopus

PubMed

Language：English   Publisher：Pharmacotherapy  

Background: Oxaliplatin-induced peripheral neuropathy (OIPN) is a major clinical challenge because it leads to discontinuation of chemotherapy. Omeprazole, a proton pump inhibitor (PPI), has been shown to prevent OIPN in a rat model. Therefore, we aimed to test whether the concomitant use of a PPI reduces oxaliplatin discontinuation due to OIPN. Methods: This retrospective study used data from 1015 patients who started treatment with oxaliplatin and evaluated two cohorts (PPI vs. non-PPI). The primary outcome measure was oxaliplatin discontinuation due to OIPN. A Kaplan–Meier curve was generated for cumulative doses and evaluated using the log-rank test and Cox proportional hazards analysis. Results: The log-rank test showed that the number of patients who discontinued oxaliplatin due to OIPN was significantly lower in the PPI group (p = 0.0264). Cox proportional hazards analysis incorporated and analyzed factors previously reported as potentially affecting neuropathy (sex, age, use of PPIs, calcium channel antagonists, opioids and adjuvant analgesics, and the CAPOX [capecitabine + oxaliplatin] regimen). The analysis suggested that the concomitant use of PPIs was a factor in reducing oxaliplatin discontinuation (adjusted hazard ratio [HR] = 0.568, 95% confidence interval [CI], 0.344–0.937, p = 0.0269). Since there were significant differences in some patient demographics between the two groups, propensity score matching was performed to align the patient demographics and then reanalyzed. After propensity score matching, the same analysis as above showed that oxaliplatin discontinuation due to OIPN was significantly less common in the PPI group (p = 0.0081); cox proportional hazards analysis showed that PPI use was a factor that significantly reduced oxaliplatin discontinuation due to OIPN (adjusted HR = 0.478, 95% CI, 0.273–0.836, p = 0.0096). Conclusions: These results suggest that concomitant PPI use may reduce oxaliplatin discontinuation due to OIPN in patients receiving oxaliplatin.

DOI： 10.1002/phar.70028

Scopus

PubMed

Language：English   Publisher：International Journal of Molecular Sciences  

Defects in Aryl hydrocarbon receptor nuclear translocator-like 1 (ARNTL), a central component of the circadian clock mechanism, may promote or inhibit the induction of inflammation by monocytes/macrophages, with varying effects on different diseases. However, ARNTL’s role in monocytes/macrophages under chronic kidney disease (CKD), which presents with systemic inflammation, is unclear. Here, we report that the expression of Arntl in monocytes promoted CKD-induced cardiac damage. The expression of G-protein-coupled receptor 68 (GPR68), which exacerbates CKD-induced cardiac disease, was regulated by ARNTL. Under CKD conditions, GPR68 expression was elevated via ARNTL, particularly in the presence of PU.1, a transcription factor specific to monocytes and macrophages. In CKD mouse models lacking monocyte-specific ARNTL, GPR68 expression in monocytes was reduced, leading to decreased cardiac damage and fibrosis despite no improvement in renal excretory capacity or renal fibrosis and increased angiotensin II production. The loss of ARNTL did not affect the expression of marker molecules, indicating the origin or differentiation of cardiac macrophages, but affected GPR68 expression only in cardiac macrophages derived from mature monocytes, highlighting the significance of the interplay between GPR68 and ARNTL in monocytes/macrophages and its influence on cardiac pathology. Understanding this complex relationship between circadian clock mechanisms and disease could help uncover novel therapeutic strategies.

DOI： 10.3390/ijms252313009

Scopus

PubMed

Language：English   Publisher：Biochemical and Biophysical Research Communications  

Among the various RNA modifications, adenosine-to-inosine RNA editing, catalyzed by adenosine deaminase acting on RNA (ADAR) family, ADAR1 and ADAR2, is the most common nucleotide conversion in mammalian cells. The pathological relevance of ADAR expression has been highlighted in recent human genetic studies. Low expression of the ADAR2 gene is correlated with a poor prognosis in breast cancer patients, but the underlying mechanism remains enigmatic. In this study, we constructed Adar2-knockdown (Adar2-KD) murine breast cancer 4T1 cells and observed their reduced susceptibility to chemotherapeutic drug doxorubicin. Downregulation of ADAR2 induced the expression of P-glycoprotein (P-gp), leading to a reduction in the intracellular accumulation of doxorubicin. The upregulation of P-gp occurred at the post-transcriptional level due to the decreased miR-195a-3p function. The search for the underlying cause of the induction of P-gp expression in Adar2-KD 4T1 cells led to the identification of circular RNA (circRNA) circHif1a as a sponge for miR-195a-3p. The enhanced expression of circHif1a inhibited miR-195a-3p function, resulting in the upregulation of P-gp expression. These results suggest that ADAR2 acts as a suppressor of circHif1a biogenesis and then allows miR-195a-3p to interfere with P-gp translation. Our findings may help to improve drug efficacy by clarifying the mechanism of chemoresistance in breast cancer.

DOI： 10.1016/j.bbrc.2024.150289

Scopus

PubMed

Language：English   Publisher：Journal of Pharmacology and Experimental Therapeutics  

A problem for patients with diabetes is the rise of complications, such as peripheral neuropathy, nephropathy, and retinopathy. Among them, peripheral neuropathy, characterized by numbness and/or hypersensitivity to pain in the extremities, is likely to develop in the early stages of diabetes. Empagliflozin (EMPA), a sodium-glucose cotransporter-2 inhibitor, exerts hypoglycemic effects by preventing glucose reabsorption in proximal tubular cells. EMPA can improve cardiovascular and renal outcomes in diabetic patients, but its suppressive effect on the development of diabetic neuropathy remains unclear. In this study, we demonstrated that optimizing the dosing schedule of EMPA suppressed the development of pain hypersensitivity in streptozotocin (STZ)-induced diabetic model mice maintained under standardized light/dark cycle conditions. A single intraperitoneal administration of STZ to mice induced hyperglycemia accompanied by pain hypersensitivity. Although EMPA did not exert anti-hypersensitivity effect on STZ-induced diabetic mice after the establishment of neuropathic pain, the development of pain hypersensitivity in the diabetic mice was significantly suppressed by daily oral administration of EMPA at the beginning of the dark phase. On the other hand, the suppressive effect was not observed when EMPA was administered at the beginning of the light phase. The hypoglycemic effect of EMPA and its stimulatory effect on urinary glucose excretion were also enhanced by the administration of the drug at the beginning of the dark phase. Nocturnal mice consumed their food mainly during the dark phase. Our results support the notion that morning administration of EMPA may be effective in suppressing the development of peripheral neuropathy in diabetic patients. SIGNIFICANCE STATEMENT Empagliflozin, a sodium-glucose cotransporter-2 inhibitor suppressed the development of neuropathic pain hypersensitivity in streptozotocin-induced diabetic model mice in a dosing time-dependent manner.

DOI： 10.1124/jpet.123.001856

Scopus

PubMed

Language：English   Publisher：Translational Research  

Chronic kidney disease (CKD) induces cardiac inflammation and fibrosis and reduces survival. We previously demonstrated that G protein-coupled receptor 68 (GPR68) promotes cardiac inflammation and fibrosis in mice with 5/6 nephrectomy (5/6Nx) and patients with CKD. However, no method of GPR68 inhibition has been found that has potential for therapeutic application. Here, we report that Cephalotaxus harringtonia var. nana extract and homoharringtonine ameliorate cardiac inflammation and fibrosis under CKD by suppressing GPR68 function. Reagents that inhibit the function of GPR68 were explored by high-throughput screening using a medicinal plant extract library (8,008 species), and we identified an extract from Cephalotaxus harringtonia var. nana as a GPR68 inhibitor that suppresses inflammatory cytokine production in a GPR68 expression-dependent manner. Consumption of the extract inhibited inflammatory cytokine expression and cardiac fibrosis and improved the decreased survival attributable to 5/6Nx. Additionally, homoharringtonine, a cephalotaxane compound characteristic of C. harringtonia, inhibited inflammatory cytokine production. Homoharringtonine administration in drinking water alleviated cardiac fibrosis and improved heart failure and survival in 5/6Nx mice. A previously unknown effect of C. harringtonia extract and homoharringtonine was revealed in which GPR68-dependent inflammation and cardiac dysfunction were suppressed. Utilizing these compounds could represent a new strategy for treating GPR68-associated diseases, including CKD.

DOI： 10.1016/j.trsl.2024.02.004

Scopus

PubMed

Language：English   Publisher：MDPI AG  

<jats:p>Prostaglandins are bioactive compounds, and the activation of their receptors affects the expression of clock genes. However, the prostaglandin F receptor (Ptgfr) has no known relationship with biological rhythms. Here, we first measured the locomotor period lengths of Ptgfr-KO (B6.129-Ptgfrtm1Sna) mice and found that they were longer under constant dark conditions (DD) than those of wild-type (C57BL/6J) mice. We then investigated the clock gene patterns within the suprachiasmatic nucleus in Ptgfr-KO mice under DD and observed a decrease in the expression of the clock gene cryptochrome 1 (Cry1), which is related to the circadian cycle. Moreover, the expression of Cry1, Cry2, and Period2 (Per2) mRNA were significantly altered in the mouse liver in Ptgfr-KO mice under DD. In the wild-type mouse, the plasma prostaglandin F2α (PGF2α) levels showed a circadian rhythm under a 12 h cycle of light–dark conditions. In addition, in vitro experiments showed that the addition of PTGFR agonists altered the amplitude of Per2::luc activity, and this alteration differed with the timing of the agonist addition. These results lead us to hypothesize that the plasma rhythm of PGF2α is important for driving clock genes, thus suggesting the involvement of PGF2α- and Ptgfr-targeting drugs in the biological clock cycle.</jats:p>

DOI： 10.3390/ijms25031841

Scopus

PubMed

CiNii Research

Language：English   Publisher：Journal of Pharmacology and Experimental Therapeutics  

Although vancomycin (VCM)—frequently used to treat drug-resistant bacterial infections—often induces acute kidney injury (AKI), discontinuation of the drug is the only effective treatment; therefore, analysis of effective avoidance methods is urgently needed. Here, we report the differences in the induction of AKI by VCM in 1/2-nephrectomized mice depending on the time of administration. Despite the lack of difference in the accumulation of VCM in the kidney between the light (ZT2) and dark (ZT14) phases, the expression of AKI markers due to VCM was observed only in the ZT2 treatment. Genomic analysis of the kidney suggested that the time of administration was involved in VCM-induced changes in monocyte and macrophage activity, and VCM had time-dependent effects on renal macrophage abundance, ATP activity, and interleukin (IL)-1b expression. Furthermore, the depletion of macrophages with clodronate abolished the induction of IL-1b and AKI marker expression by VCM administration at ZT2. This study provides evidence of the need for time-dependent pharmacodynamic considerations in the prevention of VCM-induced AKI as well as the potential for macrophage-targeted AKI therapy.

DOI： 10.1124/jpet.123.001864

Scopus

PubMed

Language：English   Publisher：Journal of Controlled Release  

Mammalians' circadian pacemaker resides in the paired suprachiasmatic nuclei (SCN). SCN control biological rhythms such as the sleep-wake rhythm and homeostatic functions of steroid hormones and their receptors. Alterations in these biological rhythms are implicated in the outcomes of pathogenic conditions such as depression, diabetes, and cancer. Chronotherapy is about optimizing treatment to combat risks and intensity of the disease symptoms that vary depending on the time of day. Thus, conditions/diseases such as allergic rhinitis, arthritis, asthma, myocardial infarction, congestive heart failure, stroke, and peptic ulcer disease, prone to manifest severe symptoms depending on the time of day, would be benefited from chronotherapy. Monitoring rhythm, overcoming rhythm disruption, and manipulating the rhythms from the viewpoints of underlying molecular clocks are essential to enhanced chronopharmacotherapy. New drugs focused on molecular clocks are being developed to improve therapeutics. In this review, we provide a critical summary of literature reports concerning (a) the rationale/mechanisms for time-dependent dosing differences in therapeutic outcomes and safety of antitumor drugs, (b) the molecular pathways underlying biological rhythms, and (c) the possibility of pharmacotherapy based on the intra- and inter-individual variabilities from the viewpoints of the clock genes.

DOI： 10.1016/j.jconrel.2023.10.049

Scopus

PubMed

Language：English   Publisher：Biochemical and Biophysical Research Communications  

Chronic kidney disease (CKD) induces an imbalance in the intestinal microbiota, affecting various physiological functions and leading to cardiovascular inflammation and fibrosis. However, the cardiotoxic impact of intestinal microbiota-derived uremic substances in advanced renal dysfunction remains unexplored. Therefore, we developed a 5/6 nephrectomy (5/6Nx) mouse model to investigate the intestinal microbiota and the effects of administering vancomycin (VCM) on the microbiota and the cardiac pathology associated with CKD. Despite VCM administration after the development of irreversible glomerulosclerosis and tubulointerstitial fibrosis, blood indoxyl sulfate and phenyl sulfate levels, which are intestinal bacteria-derived uremic substances, brain natriuretic peptide levels, and the fibrotic area in the heart were decreased. Moreover, VCM administration prevented 5/6Nx-induced weight loss and prolonged survival time. Our findings suggest that VCM-induced changes in the intestinal microbiota composition ameliorate heart failure and improve survival rates by reducing intestinal microbiota-derived cardiotoxic substances despite advanced renal dysfunction. This highlights the potential of using the intestinal microbiota as a target to prevent and treat cardiovascular conditions associated with CKD.

DOI： 10.1016/j.bbrc.2023.07.015

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Biochemical Pharmacology  

Proteins localize to their respective organelles in cells. This localization is changed by activation or repression in response to signal transduction. Therefore, the appropriate intracellular localization of proteins is important for their functions to be exerted. However, difficulties are associated with controlling the localization of endogenous proteins. In the present study, we developed a conceptually new method of controlling the intracellular localization of endogenous proteins using bispecific nanobodies (BiNbs). BiNbs recognize proteins expressed in the inner membrane, cytoskeleton, nucleus, and peroxisomes, but not in mitochondria or endoplasmic reticulum. BiNbs designed to recognize β-CATENIN and the intrinsic cytosolic protein VIMENTIN (3 × Flag β-CAT-VIM BiNbs) decreased the β-CATENIN-mediated transactivation of target genes by preventing its nuclear localization. Furthermore, 3 × Flag β-CAT-VIM BiNbs suppressed the proliferation and invasion of the VIMENTIN-expressing breast cancer cell line MDA-MB-231, but not MDA-MB-468, in which the expression of VIMENTIN was defective. The present results revealed that changes in the intracellular localization of specific proteins by BiNbs modulated the physiology and functions of cells. The development of BiNbs to recognize proteins specifically expressed in target cells may be a useful approach for eliciting cell-selective effects.

DOI： 10.1016/j.bcp.2023.115708

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Molecular Pharmacology  

Neuropathic pain associated with cancers is caused by tumor growth compressing and damaging nerves, which would also be enhanced by inflammatory factors through sensitizing nociceptor neurons. A troublesome hallmark symptom of neuropathic pain is hypersensitivity to innocuous stimuli, a condition known as "tactile allodynia", which is often refractory to NSAIDs and opioids. The involvement of chemokine CCL2 (monocyte chemoattractant protein-1) in cancer-evoked neuropathic pain is well established, but opinions remain divided as to whether CCL2 is involved in the production of tactile allodynia with tumor growth. In this study, we constructed Ccl2 knockout NCTC 2472 (Ccl2-KO NCTC) fibrosarcoma cells and conducted pain behavioral test using Ccl2-KO NCTCimplanted mice. Implantation of naïve NCTC cells around the sciatic nerves of mice produced tactile allodynia in the inoculated paw. Although the growth of Ccl2 KO NCTC-formed tumors was comparable to that of naïve NCTC-formed tumors, Ccl2-KO NCTC-bearing mice failed to show tactile pain hypersensitivity, suggesting the involvement of CCL2 in cancer-induced allodynia. Subcutaneous administration of controlled-release nanoparticles containing the CCL2 expression inhibitor NS-3-008 (1-benzyl-3-hexylguanidine) significantly attenuated tactile allodynia in naïve NCTC-bearing mice accompanied by a reduction of CCL2 content in tumor masses. Our present findings suggest that inhibition of CCL2 expression in cancer cells is a useful strategy to attenuate tactile allodynia induced by tumor growth. Development of a controlled-release system of CCL2 expression inhibitormay be a preventative option for the treatment of cancer-evoked neuropathic pain.

DOI： 10.1124/molpharm.123.000690

Scopus

PubMed

Language：English   Publisher：Biochemical and Biophysical Research Communications  

Renewal of retinal photoreceptor outer segments is conducted through daily shedding of distal photoreceptor outer segment tips and subsequent their phagocytosis by the adjacent retinal pigment epithelium (RPE) monolayer. Dysregulation of the diurnal clearance of photoreceptor outer segment tips has been implicated in age-related retinal degeneration, but it remains to be clarified how the circadian phagocytic activity of RPE cells is modulated by senescence. In this study, we used the human RPE cell line ARPE-19 to investigate whether hydrogen peroxide (H<inf>2</inf>O<inf>2</inf>)-induced senescence in ARPE-19 cells alters the circadian rhythm of their phagocytic activity. After synchronization of the cellular circadian clock by dexamethasone treatment, the phagocytic activity of normal ARPE-19 cells exhibited significant 24-h oscillation, but this oscillation was modulated by senescence. The phagocytic activity of senescent ARPE-19 cells increased constantly throughout the 24-h period, which still exhibited blunted circadian oscillation, accompanied by an alteration in the rhythmic expression of circadian clock genes and clock-controlled phagocytosis-related genes. The expression levels of REV-ERBα, a molecular component of the circadian clock, were constitutively increased in senescent ARPE-19 cells. Furthermore, pharmacological activation of REV-ERBα by its agonist SR9009 enhanced the phagocytic activity of normal ARPE-19 cells and increased the expression of clock-controlled phagocytosis-related genes. Our present findings extend to understand the role of circadian clock in the alteration of phagocytic activity in RPE during aging. Constitutive enhancement of phagocytic activity of senescent RPE may contribute to age-related retinal degeneration.

DOI： 10.1016/j.bbrc.2023.03.070

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Journal of Biochemistry  

Diurnal oscillations in the expression of several types of cell surface transporters have been demonstrated in the intestinal epithelial cells, which are mainly generated at transcriptional or degradation processes. Concentrative nucleoside transporter-2 (CNT2) is expressed at the apical site of intestinal epithelial cells and contributes to the uptake of nucleosides and their analogs from the intestinal lumen into the epithelial cells. In this study, we demonstrated that the localization of CNT2 protein in the plasma membrane of mouse intestinal epithelial cells exhibited a diurnal oscillation without changing its protein level in the whole cell. The scaffold protein PDZK1 interacted with CNT2 and stabilized its plasmalemmal localization. The expression of PDZK1 was under the control of molecular components of the circadian clock. Temporal accumulation of PDZK1 protein in intestinal epithelial cells enhanced the plasmalemmal localization of CNT2 at certain times of the day. The temporal increase in CNT2 protein levels at the plasma membrane also facilitated the uptake of adenosine into the intestinal epithelial cells. These results suggest a novel molecular mechanism for the diurnal localization of cell surface transporters and extend our understanding of the biological clock system that generates apparent physiological rhythms.

DOI： 10.1093/jb/mvad035

Scopus

PubMed

Language：English   Publisher：American Chemical Society (ACS)  

Detection of metabolic activity enables us to reveal the inherent metabolic state of cells and elucidate mechanisms underlying cellular homeostasis and growth. However, a fluorescence approach for the study of metabolic pathways is still largely unexplored. Herein, we have developed a new chemical probe for the fluorescence-based detection of fatty acid β-oxidation (FAO), a key process in lipid catabolism, in cells and tissues. This probe serves as a substrate of FAO and forms a reactive quinone methide (QM) as a result of metabolic reactions. The liberated QM is covalently captured by intracellular proteins, and subsequent bio-orthogonal ligation with a fluorophore enables fluorescence analysis. This reaction-based sensing allowed us to detect FAO activity in cells at a desired emission wavelength using diverse analytical techniques including fluorescence imaging, in-gel fluorescence activity-based protein profiling (ABPP), and fluorescence-activated cell sorting (FACS). The probe was able to detect changes in FAO activity induced by chemical modulators in cultured cells. The probe was further employed for fluorescence imaging of FAO in mouse liver tissues and revealed the metabolic heterogeneity of FAO activity in hepatocytes by the combination of FACS and gene expression analysis, highlighting the utility of our probe as a chemical tool for fatty acid metabolism research.

DOI： 10.1021/jacs.3c02043

Scopus

PubMed

CiNii Research

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Publisher：Nature Synthesis  

Efficient and practical construction of deuterated molecules has been a long-standing challenge. Although α-deutero carboxylic acids are ubiquitous structural components that serve as a wide array of synthons, and are thus in high demand, α-selective and mild methods for the deuteration of carboxylic acids have remained unexplored. Here we report the development of a ternary catalytic system for the α-deuteration of carboxylic acids in high yields with excellent levels of α-deuteration. The method shows wide functional group tolerance, including the late-stage deuteration of complex molecules, pharmaceuticals and natural products. Mechanistic studies and pK <inf>a</inf> calculations indicate that the reaction proceeds through the enolization of an acyl pyridinium species. The process was applied to the synthesis of a deuterated EP3 receptor antagonist, with the deutero analogue showing increased metabolic stability in human microsomes compared with the proto compound. [Figure not available: see fulltext.]

DOI： 10.1038/s44160-022-00139-9

Scopus

Language：English   Publisher：Allergology International  

Clock genes, circadian pacemaker resides in the paired suprachiasmatic nuclei (SCN), control various circadian rhythms in many biological processes such as physiology and behavior. Clock gene regulates many diseases such as cancer, immunological dysfunction, metabolic syndrome and sleep disorders etc. Chronotherapy is especially relevant, when the risk and/or intensity of the symptoms of disease vary predicably over time as exemplified by allergic rhinitis, arthritis, asthma, myocardial infarction, congestive heart failure, stroke, and peptic ulcer disease. Dosing time influences the effectiveness and toxicity of many drugs. The pharmacodynamics of medications as well as pharmacokinetics influences chronopharmacological phenomena. To escape from host immunity in the tumor microenvironment, cancer cells have acquired several pathways. Immune checkpoint therapy targeting programmed death 1 (PD-1) and its ligand (PD-L1) interaction had been approved for the treatment of patients with several types of cancers. Circadian expression of PD-1 is identified on tumor associated macrophages (TAMs), which is rationale for selecting the most appropriate time of day for administration of PD-1/PD-L1 inhibitors. The therapies for chronic kidney disease (CKD) are urgently needed because of a global health problem. The mechanism of the cardiac complications in mice with CKD had been related the GRP68 in circulating monocytes and serum accumulation of retinol. Development of a strategy to suppress retinol accumulation will be useful to prevent the cardiac complications of CKD. Therefore, we introduce an overview of the dosing time-dependent changes in therapeutic outcome and safety of drug for immune-related diseases.

DOI： 10.1016/j.alit.2022.06.006

Scopus

PubMed

Language：English   Publisher：MDPI AG  

<jats:p>(1) Background: Oxaliplatin is used as first-line chemotherapy not only for colorectal cancer but also for gastric and pancreatic cancers. However, it induces peripheral neuropathy with high frequency as an adverse event, and there is no effective preventive or therapeutic method. (2) Methods: The effects of omeprazole, a proton pump inhibitor (PPI), on oxaliplatin-induced peripheral neuropathy (OIPN) was investigated using an in vivo model and a real-world database. (3) Results: In a rat model, oxaliplatin (4 mg/kg, i.p., twice a week for 4 weeks) caused mechanical hypersensitivity accompanied by sciatic nerve axonal degeneration and myelin sheath disorder. Repeated injection of omeprazole (5–20 mg/kg, i.p., five times per week for 4 weeks) ameliorated these behavioral and pathological abnormalities. Moreover, omeprazole did not affect the tumor growth inhibition of oxaliplatin in tumor bearing mice. Furthermore, clinical database analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) suggests that the group using omeprazole has a lower reporting rate of peripheral neuropathy of oxaliplatin-treated patients than the group not using (3.06% vs. 6.48%, p < 0.001, reporting odds ratio 0.44, 95% confidence interval 0.32–0.61). (4) Conclusions: These results show the preventing effect of omeprazole on OIPN.</jats:p>

DOI： 10.3390/ijms23168859

Scopus

PubMed

CiNii Research

Language：English   Publisher：Journal of Biological Chemistry  

Multidrug resistance–associated protein 4 (MRP4), a member of the C subfamily of ATP-binding cassette transporters, is highly expressed in the kidneys of mammals and is responsible for renal elimination of numerous drugs. Adenosine deaminase acting on RNA 1 (ADAR1) has been reported to regulate gene expression by catalyzing adenosine-to-inosine RNA editing reactions; however, potential roles of ADAR1 in the regulation of MRP4 expression have not been investigated. In this study, we found that downregulation of ADAR1 increased the expression of MRP4 in human renal cells at the posttranscriptional level. Luciferase reporter assays and microarray analysis revealed that downregulation of ADAR1 reduced the levels of microRNA miR-381-3p, which led to the corresponding upregulation of MPR4 expression. Circular RNAs (circRNAs) are a type of closed-loop endogenous noncoding RNAs that play an essential role in gene expression by acting as miRNA sponges. We demonstrate that ADAR1 repressed the biogenesis of circRNA circHIPK3 through its adenosine-to-inosine RNA editing activity, which altered the secondary structure of the precursor of circHIPK3. Furthermore, in silico analysis suggested that circHIPK3 acts as a sponge of miR-381-3p. Indeed, we found overexpression of circHIPK3 induced the expression of MRP4 through its interference with miR-381-3p. Taken together, our study provides novel insights into regulation of the expression of xenobiotic transporters through circRNA expression by the RNA editing enzyme ADAR1.

DOI： 10.1016/j.jbc.2022.102184

Scopus

PubMed

Language：English   Publisher：Journal of Biochemistry  

In addition to diurnal rhythms in physiology and behavior, a variety of pathological conditions also exhibit marked day-night changes in symptom intensity, exemplified by allergic rhinitis, arthritis, asthma, myocardial infarction, congestive heart failure, stroke and chronic pain disorders. Currently, novel therapeutic approaches are facilitated by the development of chemical compounds targeted to key proteins that cause diurnal exacerbation of pathological events. Neuropathic pain is a chronic condition that occurs by tumor-induced nerve compression, cancer cell infiltration into the nerve, diabetes and herpes virus infection. One troublesome hallmark symptom of neuropathic pain is hypersensitivity to normally innocuous stimuli known as 'mechanical allodynia' that is often refractory to common analgesic therapies. Millions of patients worldwide presently endure neuropathic pain. We summarize the recent insights gained into the mechanism of diurnal exacerbation of neuropathic pain hypersensitivity and introduce the strategy of circadian clock-based drug development.

DOI： 10.1093/jb/mvab143

Scopus

PubMed

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)   Publisher：American Association for Cancer Research (AACR)  

<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title/>
<jats:p>Cancer cells have acquired several pathways to escape from host immunity in the tumor microenvironment. Programmed death 1 (PD-1) receptor and its ligand PD-L1 are involved in the key pathway of tumor immune escape, and immune checkpoint therapy targeting PD-1 and PD-L1 has been approved for the treatment of patients with certain types of malignancies. Although PD-1 is a well-characterized receptor on T cells, the immune checkpoint receptor is also expressed on tumor-associated macrophages (TAM), a major immune component of the tumor microenvironment. In this study, we found significant diurnal oscillation in the number of PD-1–expressing TAMs collected from B16/BL6 melanoma-bearing mice. The levels of Pdcd1 mRNA, encoding PD-1, in TAMs also fluctuated in a diurnal manner. Luciferase reporter and bioluminescence imaging analyses revealed that a NF-κB response element in the upstream region of the Pdcd1 gene is responsible for its diurnal expression. A circadian regulatory component, DEC2, whose expression in TAMs exhibited diurnal oscillation, periodically suppressed NF-κB–induced transactivation of the Pdcd1 gene, resulting in diurnal expression of PD-1 in TAMs. Furthermore, the antitumor efficacy of BMS-1, a small molecule inhibitor of PD-1/PD-L1, was enhanced by administering it at the time of day when PD-1 expression increased on TAMs. These findings suggest that identification of the diurnal expression of PD-1 on TAMs is useful for selecting the most appropriate time of day to administer PD-1/PD-L1 inhibitors.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Implications:</jats:title>
<jats:p>Selecting the most appropriate dosing time of PD-1/PD-L1 inhibitors may aid in developing cancer immunotherapy with higher efficacy.</jats:p>
</jats:sec>

DOI： 10.1158/1541-7786.MCR-21-0786

Scopus

PubMed

CiNii Research

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.7554/eLife.66155

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1038/s41467-021-23050-x

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.bcp.2021.114411

Other Link： https://pubmed.ncbi.nlm.nih.gov/33428896/

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1021/acsmedchemlett.9b00574

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1038/s41598-020-70321-6

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1021/jacs.0c07490

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/gtc.12758

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.bbrc.2019.09.021

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1111/bph.14777

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1248/bpb.b19-00546

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.bbrc.2019.02.022

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Other Link： http://www.ncbi.nlm.nih.gov/pubmed/23429911

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Other Link： http://www.ncbi.nlm.nih.gov/pubmed/23292542

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Responsible for pages：171-192   Language：Japanese   Book type：General book, introductory book for general audience

Responsible for pages：108-113   Language：Japanese   Book type：Scholarly book

「ウェット」研究でよくあるトラブルへの対処法

Event date： 2014.3

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：熊本   Country：Japan  

Event date： 2012.3

Presentation type：Symposium, workshop panel (public)  

Venue：京都国際会議場   Country：Japan  

Event date： 2011.5

Presentation type：Symposium, workshop panel (public)  

Venue：東京都   Country：Japan  

Event date： 2011.3

Presentation type：Symposium, workshop panel (public)  

Venue：静岡   Country：Japan  

Molecular machanim for the circadian expression of intestinal transporters

Event date： 2010.11

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：早稲田大学井深ホール   Country：Japan  

Event date： 2009.3

Presentation type：Oral presentation (general)  

Venue：京都市   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：San Francisco   Country：United States  

Event date： 2022.9 - 2023.9

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Event date： 2022.8

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Venue：GLOCAL HOTEL ITOSHIMA    Country：Japan  

Event date： 2022.5

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Event date： 2022.5

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Event date： 2022.5

Language：Japanese  

Country：Japan  

Event date： 2022.5

Language：Japanese  

Country：Japan  

Event date： 2022.5

Language：Japanese  

Country：Japan  

Event date： 2022.5

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Event date： 2022.5

Language：Japanese  

Country：Japan  

Event date： 2022.5

Language：English   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Event date： 2021.9

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：Web開催   Country：Japan  

Event date： 2018.10 - 2020.5

Language：English   Presentation type：Symposium, workshop panel (public)  

Venue：金沢   Country：Japan  

Event date： 2018.4

Language：English   Presentation type：Oral presentation (general)  

Venue：Taipei Medical University   Country：Taiwan, Province of China  

Event date： 2018.4

Language：English   Presentation type：Oral presentation (general)  

Venue：九州大学   Country：Japan  

Event date： 2018.3 - 2020.5

Language：English   Presentation type：Symposium, workshop panel (public)  

Venue：大阪   Country：Japan  

Event date： 2016.11

Language：English   Presentation type：Symposium, workshop panel (public)  

Venue：東京都   Country：Japan  

Event date： 2016.3

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：横浜市   Country：Japan  

Event date： 2013.12

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：京都   Country：Japan  

Event date： 2013.11

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：東京   Country：Japan  

Event date： 2013.11 - 2013.10

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：大阪   Country：Japan  

Event date： 2013.10

Language：English   Presentation type：Symposium, workshop panel (public)  

Venue：東京   Country：Japan  

Event date： 2013.6

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：熊本   Country：Japan  

Event date： 2010.12

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：長崎大学薬学部   Country：Japan  

Event date： 2010.11

Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2010.9

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：鹿児島市民会館   Country：Japan  

Event date： 2010.7

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：広島国際会議場   Country：Japan  

Event date： 2009.7

Presentation type：Symposium, workshop panel (public)  

Venue：京都   Country：Japan  

Event date： 2008.11

Presentation type：Oral presentation (general)  

Venue：Fukuoka   Country：Japan  

Event date： 2008.11

Presentation type：Symposium, workshop panel (public)  

Venue：岡山大学   Country：Japan  

Event date： 2008.7

Presentation type：Oral presentation (general)  

Country：Japan  

Venue：Williamsburg   Country：United States  

Presentation type：Symposium, workshop panel (public)  

Venue：千葉   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：Sapporo   Country：Japan  

Presentation type：Oral presentation (general)  

Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：東京   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：Yeungnam University   Country：Korea, Republic of  

Presentation type：Symposium, workshop panel (public)  

Venue：東京   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：Kanazawa   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：名古屋市   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：Tokyo   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：Tokyo   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：Tokyo   Country：Japan  

Presentation type：Oral presentation (general)  

Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：東京   Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：京都   Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：福岡   Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Country：Japan  

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Venue：東京   Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：横浜   Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：東京   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：京都   Country：Japan  

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：福岡   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：兵庫県   Country：Japan  

Presentation type：Symposium, workshop panel (public)  

Venue：金沢市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：岐阜市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：松山市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：鹿児島市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：鹿児島市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：鹿児島市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：鹿児島市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：那覇市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：熊本市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：熊本市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：熊本市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：熊本市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：Kanazawa   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：熊本市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：札幌市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：岐阜市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：長崎市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：オンライン   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：福岡市   Country：Japan  

Presentation type：Oral presentation (general)  

Venue：オンライン   Country：Japan  

Language：Japanese  

Language：Japanese  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

DOI： doi.org/10.2745/dds.32.418

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：12

Type：Competition, symposium, etc. 

Number of participants：2,000

Type：Competition, symposium, etc. 

Number of participants：1,000

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：17

Type：Competition, symposium, etc. 

Number of participants：150

Type：Competition, symposium, etc. 

Number of participants：500

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：15

Type：Competition, symposium, etc. 

Number of participants：300

Type：Competition, symposium, etc. 

Number of participants：300

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：12

Number of peer-reviewed articles in Japanese journals：1

Type：Competition, symposium, etc. 

Number of participants：1,500

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：13

Number of peer-reviewed articles in Japanese journals：2

Type：Competition, symposium, etc. 

Number of participants：500

Type：Competition, symposium, etc. 

Number of participants：500

Type：Academic society, research group, etc. 

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：8

Number of peer-reviewed articles in Japanese journals：1

Proceedings of domestic conference Number of peer-reviewed papers：95

Type：Competition, symposium, etc. 

Number of participants：180

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：4

Number of peer-reviewed articles in Japanese journals：2

Type：Competition, symposium, etc. 

Number of participants：300

Type：Peer review 

Number of peer-reviewed articles in foreign language journals：5

Number of peer-reviewed articles in Japanese journals：1

Proceedings of domestic conference Number of peer-reviewed papers：120

Type：Competition, symposium, etc. 

Number of participants：2,000

Type：Competition, symposium, etc. 

Number of participants：200